On Friday, Shares of Chicago Bridge & Iron Company N.V. (NYSE:CBI), gained 4.66% to $49.87.
Chicago Bridge & Iron Company, declared its Lake Charles fabrication facility has extended its role for the fabrication of structural and mechanical modules and other components for the AP1000® nuclear power projects in Georgia and South Carolina.
On a previous earnings call, CB&I had stated the work at Lake Charles would be substantially complete by the end of April 2015. With the additional modules and other key components, the nuclear work at the facility now will continue into next year.
CB&I and its consortium partner Westinghouse are constructing two AP1000 nuclear power units at the Vogtle Electric Generating Plant near Waynesboro, Georgia, and two units at the V.C. Summer Nuclear Station near Jenkinsville, South Carolina. These are the first new nuclear power units being built in the United States in more than 30 years.
Chicago Bridge & Iron Company N.V. provides conceptual design, technology, engineering, procurement, fabrication, modularization, construction, commissioning, maintenance, program administration, and environmental services worldwide.
At the end of Friday’s trade, Shares of WisdomTree Investments, Inc. (NASDAQ:WETF), jumped 4.62% to $19.92.
WisdomTree Investments, stated net income of $12.1 million for the first quarter of 2015 or $0.09 per share on a fully diluted basis. This compares to $30.2 million in the first quarter of 2014 (which comprised of a non-recurring tax benefit of $13.7 million) and $9.6 million in the fourth quarter of 2014. Comprised of in the quarter was a loss of $1.8 million, or $0.01 per diluted EPS, associated with the Company`s European listed ETP business, which was attained in April 2014.
WisdomTree CEO and President Jonathan Steinberg said, “We stated a record $13.5 billion in net inflows in the first quarter in the U.S., making WisdomTree one of the fastest-growing companies within the ETF and broader asset administration industry in 2015 to date. WisdomTree`s industry-leading growth underscores our ability to identify and disseminate useful and differentiated investment solutions to an ever-growing ETF market. We also recorded record revenues and pre-tax earnings in the quarter.”
“Now the sixth largest ETP sponsor in the world with $61.2 billion in AUM globally, we are ongoing to experience strong organic growth in the second quarter, led by our currency hedged equity ETFs. Importantly, we are ongoing to plant the seeds for future growth as we execute against the planned growth initiatives we formerly outlined for the year, counting investments in people, products and technology.”
WisdomTree Investments, Inc., through its auxiliaries, operates as an exchange-traded funds (ETFs) sponsor and asset manager. It offers ETFs in equities, currency, fixed income, and alternatives asset classes.
Arrow Electronics, Inc. (NYSE:ARW), ended its last trade with 4.59% gain, and closed at $62.45.
Arrow Electronics, declared the successful completion of the acquisition of ATM Electronic Corp., a leading electronic component distributor headquartered in Taipei, Taiwan with substantial operations in China.
Arrow Electronics, Inc. provides products, services, and solutions to industrial and commercial users of electronic components and enterprise computing solutions worldwide. The company operates in two segments, Global Components and Global Enterprise Computing Solutions.
Finally, Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), closed at $6.67, with 4.55% gain.
Pernix Therapeutics Holdings, declared financial results for the first quarter ended March 31, 2015.
Highlights of and subsequent to the quarter:
- Attained the Zohydro ER franchise from Zogenix, Inc. for $80.9 million in upfront cash, about 1.7 million shares of Pernix common stock, and potential regulatory and commercial milestone payments;
- Raised $130 million of gross proceeds through a private offering of 4.25% Convertible Senior Notes due 2021, funding the cash portion of the Zohydro® ER franchise acquisition and strengthening the Company’s balance sheet;
- Pernix’s supplemental New Drug Application for Treximet® (sumatriptan / naproxen sodium) for use in adolescent patients, age 12 – 17, for the acute treatment of migraine with or without aura, was accepted for filing with priority review; FDA action is predictable by May 14, 2015; and,
- Treximet® was granted pediatric exclusivity by the FDA, which will extend U.S. market exclusivity associated with the Orange Book listing for Treximet’s patents by an additional six months.
Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells branded and generic pharmaceutical products. The company’s product comprise CEDAX, an oral cephalosporin used for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza, or streptococcus pyogene; Zutripro, Rezira, and Vituz for the relief of cough and nasal congestion; and OMECLAMOX-PAK a gastroenterology product.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
